United States Biotechnology & Medical Research

Aprea Therapeutics Inc (APRE)

Track

Track

Aprea Therapeutics Inc has recorded no insider trading activity within the last ninety days. The most recent transactions occurred on January 30, 2026, when executives Gilad Oren and John P. Hamill purchased shares. Prior to this period, various leadership members engaged in multiple acquisition events throughout late 2025.
Ticker: APRE Exchange: NSM
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Aprea Therapeutics Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
2.6
Hamill John P. SrVP/CFO/Prin Fin & Acct Ofcr Officer
Transaction date
Purchase
Price
430.12
Quantity 34,073 -47.8%
Value US$4,597,741
2.2
Gilad Oren President/CEO Executive Director
Transaction date
Purchase
Price
477.45
Quantity 79,843 +19.5%
Value US$318,037
1.8
Duey Marc Non-Executive Director
Transaction date
Purchase
Price
366.34
Quantity 65,859 +21.4%
Value US$401,203
2.6
Hamill John P. SrVP/CFO/Prin Fin & Acct Ofcr Officer
Transaction date
Purchase
Price
1.17
Quantity 5,000 +22.0%
Value US$5,825
2.2
Gilad Oren President/CEO Executive Director
Transaction date
Purchase
Price
1.80
Quantity 2,497 +0.7%
Value US$4,495
2.2
Gilad Oren President/CEO Executive Director
Transaction date
Purchase
Price
1.87
Quantity 3,003 +0.9%
Value US$5,616
2.2
Gilad Oren President/CEO Executive Director
Transaction date
Purchase
Price
3.92
Quantity 500 +0.2%
Value US$1,958
1.8
Duey Marc Non-Executive Director
Transaction date
Sale
Price
4.58
Quantity 6,462 -2.7%
Value US$29,583
1.8
Duey Marc Non-Executive Director
Transaction date
Purchase
Price
4.39
Quantity 30,000 +14.3%
Value US$131,700
2.2
Gilad Oren President/CEO Executive Director
Transaction date
Purchase
Price
2.90
Quantity 250 +0.1%
Value US$725
1.8
Duey Marc Non-Executive Director
Transaction date
Purchase
Price
2.58
Quantity 190 +0.1%
Value US$490
2.2
Gilad Oren President/CEO Executive Director
Transaction date
Purchase
Price
2.59
Quantity 1,000 +0.3%
Value US$2,590
2.6
Hamill John P. SrVP/CFO/Prin Fin & Acct Ofcr Officer
Transaction date
Purchase
Price
2.46
Quantity 50 +0.3%
Value US$123
2.9
Seizinger Bernd R. Non-Executive Director
Transaction date
Purchase
Price
2.68
Quantity 10,000 +28.8%
Value US$26,800
2.2
Gilad Oren President/CEO Executive Director
Transaction date
Purchase
Price
2.54
Quantity 150 +0.0%
Value US$381
2.6
Hamill John P. SrVP/CFO/Prin Fin & Acct Ofcr Officer
Transaction date
Purchase
Price
2.61
Quantity 450 +2.4%
Value US$1,174
2.6
Hamill John P. SrVP/CFO/Prin Fin & Acct Ofcr Officer
Transaction date
Purchase
Price
7.29
Quantity 1,010 +7.0%
Value US$7,363
2.9
Seizinger Bernd R. Non-Executive Director
Transaction date
Purchase
Price
7.29
Quantity 6,860 +25.6%
Value US$50,009
3.5
HENNEMAN JOHN B III Non-Executive Director
Transaction date
Purchase
Price
7.29
Quantity 6,860 +536.4%
Value US$50,009
2.2
Gilad Oren President, CEO Executive Director
Transaction date
Purchase
Price
7.29
Quantity 2,000 +0.6%
Value US$14,580
2.9
Seizinger Bernd R. Non-Executive Director
Transaction date
Purchase
Price
3.68
Quantity 6,029 +29.7%
Value US$22,192
2.9
Seizinger Bernd R. Non-Executive Director
Transaction date
Purchase
Price
3.63
Quantity 4,068 +25.1%
Value US$14,764
2.9
Seizinger Bernd R. Non-Executive Director
Transaction date
Purchase
Price
0.71
Quantity 50,000 +18.6%
Value US$35,500
2.2
SCHADE CHRISTIAN S Chairman & CEO Executive Director
Transaction date
Purchase
Price
0.64
Quantity 37,500 +14.7%
Value US$24,124
Attar Eyal C. SVP, Chief Medical Officer Officer
Transaction date
Planned sale
Price
1.73
Quantity 36,000 -43.4%
Value US$62,280
Korbel Gregory Alan SVP, Chief Business Officer Officer
Transaction date
Planned sale
Price
3.96
Quantity 27,500 -61.6%
Value US$108,900
Korbel Gregory Alan SVP, Chief Business Officer Officer
Transaction date
Planned sale
Price
5.00
Quantity 27,500 -61.6%
Value US$137,500
Korbel Gregory Alan SVP, Chief Business Officer Officer
Transaction date
Planned sale
Price
4.89
Quantity 27,500 -61.6%
Value US$134,475
Abrahmsen Lars B. SVP, Chief Scientific Officer Officer
Transaction date
Planned sale
Price
4.89
Quantity 50,000 -72.5%
Value US$244,500
3.2
Redmile Group, LLC Large shareholder
Transaction date
Sale
Price
5.80
Quantity 5,863 -0.3%
Value US$34,005
3.2
Redmile Group, LLC Large shareholder
Transaction date
Sale
Price
5.58
Quantity 494,137 -21.8%
Value US$2,757,284
3.6
5AM Ventures IV, L.P. Former 10% holder
Transaction date
Sale
Price
25.30
Quantity 175,000 -55.8%
Value US$4,427,500
3.2
KDev Investments AB Large shareholder
Transaction date
Sale
Price
34.55
Quantity 241,703 -10.8%
Value US$8,350,839
3.6
5AM Ventures IV, L.P. Large shareholder
Transaction date
Sale
Price
33.30
Quantity 19,836 -6.0%
Value US$660,539
3.6
5AM Ventures IV, L.P. Large shareholder
Transaction date
Sale
Price
33.30
Quantity 4,807 -6.0%
Value US$160,073
3.1
ROCKLAGE SCOTT M Non-Executive Director Large shareholder
Transaction date
Sale
Price
33.30
Quantity 4,807 -6.0%
Value US$160,073
3.6
5AM Ventures IV, L.P. Large shareholder
Transaction date
Sale
Price
33.30
Quantity 115,357 -6.0%
Value US$3,841,388
3.1
ROCKLAGE SCOTT M Non-Executive Director Large shareholder
Transaction date
Sale
Price
33.30
Quantity 115,357 -6.0%
Value US$3,841,388
3.6
5AM Ventures IV, L.P. Large shareholder
Transaction date
Sale
Price
28.75
Quantity 9,800 -10.8%
Value US$281,776
3.1
ROCKLAGE SCOTT M Non-Executive Director Large shareholder
Transaction date
Sale
Price
28.75
Quantity 9,800 -10.8%
Value US$281,776
3.1
ROCKLAGE SCOTT M Non-Executive Director Large shareholder
Transaction date
Sale
Price
28.75
Quantity 235,200 -10.8%
Value US$6,762,635
3.6
5AM Ventures IV, L.P. Large shareholder
Transaction date
Sale
Price
28.75
Quantity 235,200 -10.8%
Value US$6,762,635
3.1
ROCKLAGE SCOTT M Non-Executive Director
Transaction date
Sale
Price
35.15
Quantity 10,200 -10.1%
Value US$358,530
3.6
5AM Ventures IV, L.P. Large shareholder
Transaction date
Sale
Price
35.15
Quantity 10,200 -10.1%
Value US$358,530
3.6
5AM Ventures IV, L.P. Large shareholder
Transaction date
Sale
Price
35.15
Quantity 244,800 -10.1%
Value US$8,604,720
3.1
ROCKLAGE SCOTT M Non-Executive Director
Transaction date
Sale
Price
35.15
Quantity 244,800 -10.1%
Value US$8,604,720
3.2
KDev Investments AB Large shareholder
Transaction date
Sale
Price
31.25
Quantity 210,548 -8.6%
Value US$6,579,625
3.6
5AM Ventures IV, L.P. Large shareholder
Transaction date
Purchase
Price
15.00
Quantity 333,333 +inf%
Value US$4,999,995
3.2
Redmile Group, LLC Large shareholder
Transaction date
Purchase
Price
15.00
Quantity 400,000 +21.4%
Value US$6,000,000
Korbel Gregory Alan VP of Business Dev't
Transaction date
Purchase
Price
15.00
Quantity 500 +inf%
Value US$7,500
0.6
HealthCap VII, L.P. Large shareholder
Transaction date
Purchase
Price
15.00
Quantity 266,667 +12.7%
Value US$4,000,005
Coiante Scott M SVP, Chief Financial Officer
Transaction date
Purchase
Price
15.00
Quantity 2,500 +inf%
Value US$37,500
Attar Eyal C. SVP, Chief Medical Officer
Transaction date
Purchase
Price
15.00
Quantity 200 +inf%
Value US$3,000
Attar Eyal C. SVP, Chief Medical Officer
Transaction date
Purchase
Price
15.00
Quantity 200 +inf%
Value US$3,000
3.5
HENNEMAN JOHN B III
Transaction date
Purchase
Price
15.00
Quantity 5,000 +inf%
Value US$75,000
2.2
SCHADE CHRISTIAN S President & CEO
Transaction date
Purchase
Price
15.00
Quantity 5,000 +inf%
Value US$75,000
2.2
SCHADE CHRISTIAN S President & CEO
Transaction date
Purchase
Price
15.00
Quantity 1,000 +inf%
Value US$15,000
2.2
SCHADE CHRISTIAN S President & CEO
Transaction date
Purchase
Price
15.00
Quantity 1,000 +inf%
Value US$15,000
2.2
SCHADE CHRISTIAN S President & CEO
Transaction date
Purchase
Price
15.00
Quantity 1,000 +inf%
Value US$15,000
2.2
SCHADE CHRISTIAN S President & CEO
Transaction date
Purchase
Price
15.00
Quantity 1,000 +inf%
Value US$15,000
2.2
SCHADE CHRISTIAN S President & CEO
Transaction date
Purchase
Price
15.00
Quantity 1,000 +inf%
Value US$15,000
2.2
SCHADE CHRISTIAN S President & CEO
Transaction date
Purchase
Price
15.00
Quantity 1,000 +inf%
Value US$15,000
0.6
Christenson Johan
Transaction date
Purchase
Price
15.00
Quantity 266,667 +12.7%
Value US$4,000,005
Magni Guido
Transaction date
Purchase
Price
15.00
Quantity 6,500 +inf%
Value US$97,500
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-02-02 2026-01-30 B Purchase
2.6
Hamill John P.

SrVP/CFO/Prin Fin & Acct Ofcr

Officer
34,073 -47.8%
430.12
US$4,597,741 		34,073 -47.8% 430.12 US$4,597,741
2026-02-02 2026-01-30 B Purchase
2.2
Gilad Oren

President/CEO

Executive Director
79,843 +19.5%
477.45
US$318,037 		79,843 +19.5% 477.45 US$318,037
2025-12-11 2025-12-10 B Purchase
1.8
Duey Marc
Non-Executive Director
65,859 +21.4%
366.34
US$401,203 		65,859 +21.4% 366.34 US$401,203
2025-12-11 2025-12-10 B Purchase
2.6
Hamill John P.

SrVP/CFO/Prin Fin & Acct Ofcr

Officer
5,000 +22.0%
1.17
US$5,825 		5,000 +22.0% 1.17 US$5,825
2025-04-04 2025-04-03 B Purchase
2.2
Gilad Oren

President/CEO

Executive Director
2,497 +0.7%
1.80
US$4,495 		2,497 +0.7% 1.80 US$4,495
2025-04-04 2025-04-03 B Purchase
2.2
Gilad Oren

President/CEO

Executive Director
3,003 +0.9%
1.87
US$5,616 		3,003 +0.9% 1.87 US$5,616
2024-10-24 2024-10-23 B Purchase
2.2
Gilad Oren

President/CEO

Executive Director
500 +0.2%
3.92
US$1,958 		500 +0.2% 3.92 US$1,958
2024-10-25 2024-10-18 S Sale
1.8
Duey Marc
Non-Executive Director
6,462 -2.7%
4.58
US$29,583 		6,462 -2.7% 4.58 US$29,583
2024-10-17 2024-10-16 B Purchase
1.8
Duey Marc
Non-Executive Director
30,000 +14.3%
4.39
US$131,700 		30,000 +14.3% 4.39 US$131,700
2024-10-16 2024-10-15 B Purchase
2.2
Gilad Oren

President/CEO

Executive Director
250 +0.1%
2.90
US$725 		250 +0.1% 2.90 US$725
2024-10-16 2024-10-14 B Purchase
1.8
Duey Marc
Non-Executive Director
190 +0.1%
2.58
US$490 		190 +0.1% 2.58 US$490
2024-10-15 2024-10-14 B Purchase
2.2
Gilad Oren

President/CEO

Executive Director
1,000 +0.3%
2.59
US$2,590 		1,000 +0.3% 2.59 US$2,590
2024-10-16 2024-10-11 B Purchase
2.6
Hamill John P.

SrVP/CFO/Prin Fin & Acct Ofcr

Officer
50 +0.3%
2.46
US$123 		50 +0.3% 2.46 US$123
2024-10-15 2024-10-11 B Purchase
2.9
Seizinger Bernd R.
Non-Executive Director
10,000 +28.8%
2.68
US$26,800 		10,000 +28.8% 2.68 US$26,800
2024-10-15 2024-10-10 B Purchase
2.2
Gilad Oren

President/CEO

Executive Director
150 +0.0%
2.54
US$381 		150 +0.0% 2.54 US$381
2024-10-15 2024-10-10 B Purchase
2.6
Hamill John P.

SrVP/CFO/Prin Fin & Acct Ofcr

Officer
450 +2.4%
2.61
US$1,174 		450 +2.4% 2.61 US$1,174
2024-03-14 2024-03-13 B Purchase
2.6
Hamill John P.

SrVP/CFO/Prin Fin & Acct Ofcr

Officer
1,010 +7.0%
7.29
US$7,363 		1,010 +7.0% 7.29 US$7,363
2024-03-14 2024-03-13 B Purchase
2.9
Seizinger Bernd R.
Non-Executive Director
6,860 +25.6%
7.29
US$50,009 		6,860 +25.6% 7.29 US$50,009
2024-03-14 2024-03-13 B Purchase
3.5
HENNEMAN JOHN B III
Non-Executive Director
6,860 +536.4%
7.29
US$50,009 		6,860 +536.4% 7.29 US$50,009
2024-03-14 2024-03-13 B Purchase
2.2
Gilad Oren

President, CEO

Executive Director
2,000 +0.6%
7.29
US$14,580 		2,000 +0.6% 7.29 US$14,580
2023-06-08 2023-06-07 B Purchase
2.9
Seizinger Bernd R.
Non-Executive Director
6,029 +29.7%
3.68
US$22,192 		6,029 +29.7% 3.68 US$22,192
2023-06-08 2023-06-06 B Purchase
2.9
Seizinger Bernd R.
Non-Executive Director
4,068 +25.1%
3.63
US$14,764 		4,068 +25.1% 3.63 US$14,764
2022-05-19 2022-05-18 B Purchase
2.9
Seizinger Bernd R.
Non-Executive Director
50,000 +18.6%
0.71
US$35,500 		50,000 +18.6% 0.71 US$35,500
2022-05-19 2022-05-18 B Purchase
2.2
SCHADE CHRISTIAN S

Chairman & CEO

Executive Director
37,500 +14.7%
0.64
US$24,124 		37,500 +14.7% 0.64 US$24,124
2022-03-01 2022-02-28 PlS Planned sale
Attar Eyal C.

SVP, Chief Medical Officer

Officer
36,000 -43.4%
1.73
US$62,280 		36,000 -43.4% 1.73 US$62,280
2021-12-03 2021-12-01 PlS Planned sale
Korbel Gregory Alan

SVP, Chief Business Officer

Officer
27,500 -61.6%
3.96
US$108,900 		27,500 -61.6% 3.96 US$108,900
2021-11-03 2021-11-01 PlS Planned sale
Korbel Gregory Alan

SVP, Chief Business Officer

Officer
27,500 -61.6%
5.00
US$137,500 		27,500 -61.6% 5.00 US$137,500
2021-10-05 2021-10-01 PlS Planned sale
Korbel Gregory Alan

SVP, Chief Business Officer

Officer
27,500 -61.6%
4.89
US$134,475 		27,500 -61.6% 4.89 US$134,475
2021-10-05 2021-10-01 PlS Planned sale
Abrahmsen Lars B.

SVP, Chief Scientific Officer

Officer
50,000 -72.5%
4.89
US$244,500 		50,000 -72.5% 4.89 US$244,500
2021-02-16 2020-12-28 S Sale
3.2
Redmile Group, LLC
Large shareholder
5,863 -0.3%
5.80
US$34,005 		5,863 -0.3% 5.80 US$34,005
2021-02-16 2020-12-28 S Sale
3.2
Redmile Group, LLC
Large shareholder
494,137 -21.8%
5.58
US$2,757,284 		494,137 -21.8% 5.58 US$2,757,284
2020-10-07 2020-10-05 S Sale
3.6
5AM Ventures IV, L.P.

Former 10% holder
175,000 -55.8%
25.30
US$4,427,500 		175,000 -55.8% 25.30 US$4,427,500
2020-07-07 2020-07-07 S Sale
3.2
KDev Investments AB
Large shareholder
241,703 -10.8%
34.55
US$8,350,839 		241,703 -10.8% 34.55 US$8,350,839
2020-06-18 2020-06-16 S Sale
3.6
5AM Ventures IV, L.P.
Large shareholder
19,836 -6.0%
33.30
US$660,539 		19,836 -6.0% 33.30 US$660,539
2020-06-18 2020-06-16 S Sale
3.6
5AM Ventures IV, L.P.
Large shareholder
4,807 -6.0%
33.30
US$160,073 		4,807 -6.0% 33.30 US$160,073
2020-06-18 2020-06-16 S Sale
3.1
ROCKLAGE SCOTT M
Non-Executive Director Large shareholder
4,807 -6.0%
33.30
US$160,073 		4,807 -6.0% 33.30 US$160,073
2020-06-18 2020-06-16 S Sale
3.6
5AM Ventures IV, L.P.
Large shareholder
115,357 -6.0%
33.30
US$3,841,388 		115,357 -6.0% 33.30 US$3,841,388
2020-06-18 2020-06-16 S Sale
3.1
ROCKLAGE SCOTT M
Non-Executive Director Large shareholder
115,357 -6.0%
33.30
US$3,841,388 		115,357 -6.0% 33.30 US$3,841,388
2020-06-15 2020-06-11 S Sale
3.6
5AM Ventures IV, L.P.
Large shareholder
9,800 -10.8%
28.75
US$281,776 		9,800 -10.8% 28.75 US$281,776
2020-06-15 2020-06-11 S Sale
3.1
ROCKLAGE SCOTT M
Non-Executive Director Large shareholder
9,800 -10.8%
28.75
US$281,776 		9,800 -10.8% 28.75 US$281,776
2020-06-15 2020-06-11 S Sale
3.1
ROCKLAGE SCOTT M
Non-Executive Director Large shareholder
235,200 -10.8%
28.75
US$6,762,635 		235,200 -10.8% 28.75 US$6,762,635
2020-06-15 2020-06-11 S Sale
3.6
5AM Ventures IV, L.P.
Large shareholder
235,200 -10.8%
28.75
US$6,762,635 		235,200 -10.8% 28.75 US$6,762,635
2020-05-21 2020-05-19 S Sale
3.1
ROCKLAGE SCOTT M
Non-Executive Director
10,200 -10.1%
35.15
US$358,530 		10,200 -10.1% 35.15 US$358,530
2020-05-21 2020-05-19 S Sale
3.6
5AM Ventures IV, L.P.
Large shareholder
10,200 -10.1%
35.15
US$358,530 		10,200 -10.1% 35.15 US$358,530
2020-05-21 2020-05-19 S Sale
3.6
5AM Ventures IV, L.P.
Large shareholder
244,800 -10.1%
35.15
US$8,604,720 		244,800 -10.1% 35.15 US$8,604,720
2020-05-21 2020-05-19 S Sale
3.1
ROCKLAGE SCOTT M
Non-Executive Director
244,800 -10.1%
35.15
US$8,604,720 		244,800 -10.1% 35.15 US$8,604,720
2020-04-15 2020-04-13 S Sale
3.2
KDev Investments AB
Large shareholder
210,548 -8.6%
31.25
US$6,579,625 		210,548 -8.6% 31.25 US$6,579,625
2019-10-09 2019-10-07 B Purchase
3.6
5AM Ventures IV, L.P.
Large shareholder
333,333 +inf%
15.00
US$4,999,995 		333,333 +inf% 15.00 US$4,999,995
2019-10-08 2019-10-07 B Purchase
3.2
Redmile Group, LLC
Large shareholder
400,000 +21.4%
15.00
US$6,000,000 		400,000 +21.4% 15.00 US$6,000,000
2019-10-07 2019-10-07 B Purchase
Korbel Gregory Alan

VP of Business Dev't
500 +inf%
15.00
US$7,500 		500 +inf% 15.00 US$7,500
2019-10-07 2019-10-07 B Purchase
0.6
HealthCap VII, L.P.
Large shareholder
266,667 +12.7%
15.00
US$4,000,005 		266,667 +12.7% 15.00 US$4,000,005
2019-10-07 2019-10-07 B Purchase
Coiante Scott M

SVP, Chief Financial Officer
2,500 +inf%
15.00
US$37,500 		2,500 +inf% 15.00 US$37,500
2019-10-07 2019-10-07 B Purchase
Attar Eyal C.

SVP, Chief Medical Officer
200 +inf%
15.00
US$3,000 		200 +inf% 15.00 US$3,000
2019-10-07 2019-10-07 B Purchase
Attar Eyal C.

SVP, Chief Medical Officer
200 +inf%
15.00
US$3,000 		200 +inf% 15.00 US$3,000
2019-10-07 2019-10-07 B Purchase
3.5
HENNEMAN JOHN B III
5,000 +inf%
15.00
US$75,000 		5,000 +inf% 15.00 US$75,000
2019-10-07 2019-10-07 B Purchase
2.2
SCHADE CHRISTIAN S

President & CEO
5,000 +inf%
15.00
US$75,000 		5,000 +inf% 15.00 US$75,000
2019-10-07 2019-10-07 B Purchase
2.2
SCHADE CHRISTIAN S

President & CEO
1,000 +inf%
15.00
US$15,000 		1,000 +inf% 15.00 US$15,000
2019-10-07 2019-10-07 B Purchase
2.2
SCHADE CHRISTIAN S

President & CEO
1,000 +inf%
15.00
US$15,000 		1,000 +inf% 15.00 US$15,000
2019-10-07 2019-10-07 B Purchase
2.2
SCHADE CHRISTIAN S

President & CEO
1,000 +inf%
15.00
US$15,000 		1,000 +inf% 15.00 US$15,000
2019-10-07 2019-10-07 B Purchase
2.2
SCHADE CHRISTIAN S

President & CEO
1,000 +inf%
15.00
US$15,000 		1,000 +inf% 15.00 US$15,000
2019-10-07 2019-10-07 B Purchase
2.2
SCHADE CHRISTIAN S

President & CEO
1,000 +inf%
15.00
US$15,000 		1,000 +inf% 15.00 US$15,000
2019-10-07 2019-10-07 B Purchase
2.2
SCHADE CHRISTIAN S

President & CEO
1,000 +inf%
15.00
US$15,000 		1,000 +inf% 15.00 US$15,000
2019-10-07 2019-10-07 B Purchase
Versant V Luxco S.a r.l.
333,333 +inf%
15.00
US$4,999,995 		333,333 +inf% 15.00 US$4,999,995
2019-10-07 2019-10-07 B Purchase
0.6
Christenson Johan
266,667 +12.7%
15.00
US$4,000,005 		266,667 +12.7% 15.00 US$4,000,005
2019-10-07 2019-10-07 B Purchase
0.9
Versant Vantage I, L.P.
333,333 +inf%
15.00
US$4,999,995 		333,333 +inf% 15.00 US$4,999,995
2019-10-07 2019-10-07 B Purchase
Magni Guido
6,500 +inf%
15.00
US$97,500 		6,500 +inf% 15.00 US$97,500
Explore more

More insider trading research around Aprea Therapeutics Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America